Europe Life Sciences Weekly Brief #41: The Premium on Certainty
Week of 8–14 June 2026 This was a week about the price of proof. GSK paid a premium for late-stage oncology assets already under FDA review. Roche put serious money behind a validated target through a newer modality. Europe’s medicines regulators made reliability the centre of the AI conversation. The UK edged closer to a…